These results were in line with previous studies that demonstrated that regorafenib/anti-PD-1 antibody combination therapy could inhibit tumor growth and increase survival by normalizing tumor vasculature and enhancing intratumoral CXCR3+ CD8+  T-cell infiltration in HCC cells [43], and regorafenib inhibits the recruitment of TAMs and Treg cells in tumors [44,45,46]. Here, PDCD1 is linked to hepatocellular carcinoma.